SELLAS Life Sciences
22 hedge funds and large institutions have $4.28M invested in SELLAS Life Sciences in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 10 closing their positions.
2,911% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $92K
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
1.69% more ownership
Funds ownership: 8.89% → 10.59% (+1.7%)
1% less capital invested
Capital invested by funds: $4.32M → $4.28M (-$33.3K)
21% less funds holding
Funds holding: 28 → 22 (-6)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.09M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$101K |
| 3 |
State Street
Boston,
Massachusetts
|
+$62.8K |
| 4 |
EH
Equitable Holdings
New York
|
+$42.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$18.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$144K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$131K |
| 3 |
Morgan Stanley
New York
|
-$124K |
| 4 |
VF
Virtu Financial
New York
|
-$43K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$37.9K |
SLS Hedge Fund Activity: Q1 2023 in Review
22 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2023, worth a combined $4.28M — down 0.77% from $4.32M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SLS and 4 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 7 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $3.09M. The largest seller was Millennium Management, exiting entirely with an estimated $144K sold.
- 22 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2023, down from 28 in Q4 2022.
- Funds reported $4.28M of SELLAS Life Sciences stock for Q1 2023, down 0.77% quarter-over-quarter.
- 4 funds opened new SELLAS Life Sciences positions in Q1 2023 and 10 closed out, a net change of -6 holders.
- The largest SELLAS Life Sciences buyer in Q1 2023 was Alyeska Investment Group, an estimated $3.09M added.
- The largest SELLAS Life Sciences seller in Q1 2023 was Millennium Management, an estimated $144K sold.
Based on aggregated 13F filings for Q1 2023.